Vancouver, British Columbia–(February 9, 2026) – Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE: 8BN) (“Optimi” or the “Company”), a Health Canada-licensed manufacturer of pharmaceutical psychoactive medication products, today reported that it has completed its first export of MD-MA capsules to Australia in 2026 under the Authorised Prescriber Scheme.

The export included 1,000 of Optimi’s MD-MA capsules in a standardised 60 mg dosage form, supplied for use in authorised clinical programs for the treatment of Post-Traumatic Stress Disorder (PTSD). The export followed completion of Optimi’s first 2026 production cycle, and receipt of the required Australian import permits and Health Canada export permits authorising international shipment.

Based on standard clinical protocols, this quantity of MD-MA represents sufficient supply to support over 300 authorised PTSD treatment sessions under MD-MA-assisted therapy programs.

Patient-Reported Outcomes (PROs) are being collected by the Australian National University (ANU), which is developing one of the most comprehensive real-world evidence (RWE) datasets to date on MD-MA-assisted therapy for the treatment of Post-Traumatic Stress Disorder (PTSD).

Under the current framework, the Australian Department of Veterans’ Affairs (DVA) offers reimbursement for eligible veterans receiving psychoactive-assisted therapy when delivered in accordance with program requirements.

According to the Australian Bureau of Statistics, approximately 5-6% of Australians experience PTSD in a given year, representing roughly 1.3 to 1.5 million people, with higher prevalence among veterans and first responders.

Optimi holds a Medication Establishment Licence issued by Health Canada that authorises the manufacture of the MD-MA capsules for regulated therapeutic use, including the treatment of Post-Traumatic Stress Disorder (PTSD), where permitted by local authorities.

The Company’s licensed Australian pharmacy partner acts as importer of record and national distributor, supplying authorised clinics across Australia in accordance with local regulatory requirements. This delivery enables participating clinics to proceed with MD-MA-assisted therapy for eligible patients.

Clinicians, hospital networks, and authorised programs may seek information regarding access through Mind Medicine Australia at [email protected].

For global enquiries outside of Australia, please contact [email protected].

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10615/283071_135cf3c014bb3a02_001full.jpg

About Optimi Health Corp.

Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE: 8BN) is a leading producer of prescribed psychoactive treatments for mental health therapies. As a Health Canada-licensed, GMP compliant pharmaceutical manufacturer producing validated MD-MA and botanical psilo products from two 10,000-square-foot facilities in British Columbia, Optimi supplies active pharmaceutical ingredients and finished dosage forms to regulated channels, with products currently in market for prescription use in Australia via the Authorized Prescriber Scheme and accessible in Canada through the Special Access Program. For more information, please visit www.optimihealth.ca.

Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements“), including with respect to the role of psychoactive medicines in insured mental health care. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties, and contingencies, certain of which are unknown. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions, or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward-looking statements. These statements may involve estimates, assumptions, and uncertainties that could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct, and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed in the Company’s continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.ca. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.

Featured Image @ Freepik